Lv1
58 积分 2024-03-22 加入
Venetoclax-based combination therapy in R/R DLBCL patients with failure of CAR-T therapy
1个月前
已完结
Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma
1个月前
已完结
Dual epigenetic agents plus rituximab–gemcitabine–oxaliplatin as salvage treatment in relapsed/refractory diffuse large B‐cell lymphoma patients failure of salvage chemotherapy
1个月前
已完结
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
2个月前
已完结
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
2个月前
已完结
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
2个月前
已完结
High-risk MCL: recognition and treatment
5个月前
已完结
Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma
6个月前
已关闭
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
6个月前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
6个月前
已完结
皖公网安备34019202002308
